Australia is supporting the Global Alliance for TB Drug Development (TB Alliance) to advance TB treatments through innovative research and capacity building. TB Alliance is improving outcomes for all TB patients and communities through trialling and developing shorter, simplified and more affordable treatment regimes. To ensure faster uptake and access to new life-saving TB treatments, TB Alliance has created a Manila-based peer-to-peer knowledge hub for countries to learn from other national TB programs for implementation of new guidelines and to support clinical training.

Australia is supporting Medicines Development for Global Health (MDGH) to advance the development and delivery of two medicines, moxidectin and dovramilast, for the treatment of some of the world’s most challenging, disfiguring and stigmatising infectious diseases. Scabies, lymphatic filariasis and leprosy type 2 reaction negatively impact the lives of hundreds of millions of people globally and have some of the highest reported prevalence rates in the Indo-Pacific.